Alexandria Real Estate Eq Inc Stock Price, News & Analysis

On January 4, 2022, Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced its upsized public offering of 7,000,000 shares of common stock priced at $210.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 1,050,000 shares. The offering's expected closing date is on or about January 7, 2022. The proceeds, if any, from future settlements of forward sale agreements are planned to fund acquisitions and development projects, as well as general corporate purposes.

Alexandria Real Estate Equities (NYSE: ARE) announced a public offering of 6,500,000 shares of its common stock, with a potential 30-day option for underwriters to buy an additional 975,000 shares. The financing aims to support pending acquisitions and fund development projects. The company will not initially receive proceeds from the sale, as the forward purchasers will first sell these shares to underwriters. Settlement of the forward sale agreements is expected by September 15, 2023.

On December 14, 2021, Alexandria Real Estate Equities (NYSE: ARE) announced a partnership with Camp Kita, a nonprofit organization supporting children affected by suicide. Through a significant donation, Alexandria will provide 28 acres in Acton, Maine, for a new camp facility expected to open in summer 2023. The camp aims to serve as a nurturing space for young survivors, offering resources for grief management and community connection. Alexandria's broader social responsibility efforts include addressing various societal challenges, emphasizing their commitment to enhancing human health and quality of life.

Alexandria Real Estate Equities (NYSE: ARE) declared a quarterly cash dividend of $1.15 per common share for Q4 2021, payable on January 14, 2022. This brings the total dividend for 2021 to $4.48 per share, a 6% increase from 2020. The dividend reflects the company's strong net cash from operating activities while maintaining a low 58% funds from operations payout ratio, allowing for reinvestment in development projects. Alexandria is dedicated to growth in life sciences and technology sectors.

Alexandria Real Estate Equities, Inc. (NYSE: ARE) will host a conference call and audio webcast on February 1, 2022, at 3:00 p.m. ET to discuss its fourth quarter and year-end 2021 operating and financial results. The results will be released after the market closes on January 31, 2022. Interested participants can join the call by dialing (833) 366-1125 (U.S.) or (412) 902-6738, or listen via the company’s website. A replay will be available from 5:00 p.m. ET on February 1 until February 8, 2022.

Alexandria Venture Investments, affiliated with Alexandria Real Estate Equities (ARE), has intensified its investments in the agrifoodtech sector, recognized as one of the top five U.S. investors in 2021 by AgFunder. The sector has seen growth from $8.9 billion in 2016 to $24 billion in early 2021. Alexandria aims to double its investment this year, focusing on companies innovating in sustainable agriculture and human health. The firm supports various companies, including GreenLight Biosciences and Bear Flag Robotics, further enhancing its portfolio.

On November 16, 2021, Alexandria Real Estate Equities (NYSE: ARE) announced plans to enhance R&D and next-gen manufacturing in Research Triangle, N.C. The company is partnering with biotechnology firms and acquiring development sites to help these companies control their medicine quality and supply chains. Alexandria's recent acquisition includes 95 acres for biomanufacturing centers. They aim to foster integrated manufacturing capabilities, crucial for developing complex medicines. Alexandria's market cap stands at $38.6 billion, with a significant presence in major innovation hubs across North America.

On October 25, 2021, Alexandria Real Estate Equities (NYSE:ARE) announced its financial results for Q3 2021, showing total revenues of $547.8 million, a 0.5% increase from Q3 2020. Net income attributable to common stockholders rose to $101.3 million ($0.67 per share), reflecting strong demand for office and laboratory spaces. The company secured a 15-year lease with Moderna for a new HQ, marking its largest life science lease. Year-to-date leasing volume reached 5.4 million RSF, with a 39.4% rental rate increase. S&P upgraded its credit outlook to BBB+/Positive, emphasizing strong fundamentals.